A panel of mouse monoclonal antibodies were generated against AAV8 and AAV9.
The new MAbs recognize conformational epitopes.
In vitro virus neutralization by new antibodies suggests recognition of functional regions.
The new MAbs provide tools for characterization of AAV8 and AAV9 variants being developed for improved therapeutic efficacy.